Back to top
more

Urogen Pharma (URGN)

(Delayed Data from NSDQ)

$13.78 USD

13.78
619,719

+0.81 (6.25%)

Updated May 15, 2024 04:00 PM ET

After-Market: $13.73 -0.05 (-0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UROGEN PHARMA (URGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -6.36% and 0.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of 7.14% and -10.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

UroGen (URGN) Looks Good: Stock Adds 8.1% in Session

by Zacks Equity Research

UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.

UroGen Pharma Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.

The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

    5 Best Performing IPOs of 2017

    by Zacks Equity Research

    The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.